Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement.On.
(PLX AI) - Genmab shares rose 2.7% after Nordea raised its price target on the stock to DKK 3,304 from DKK 3,191 and reiterated a buy recommendation. • Genmab has good risk/reward for arbitration in its